이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)

2026년 9월 14일 업데이트: InSilico Medicine Hong Kong Limited

A Prospective Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Safety of Rentosertib (INS018_055) Administered Orally Over 52 Weeks in Patients With Idiopathic Pulmonary Fibrosis (IPF)

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Rentosertib (INS018_055) administered orally in Patients with Idiopathic Pulmonary Fibrosis.

The purpose of this study is to evaluate if Rentosertib (INS018_055) works to treat patients with Idiopathic Pulmonary Fibrosis in adults. It will also learn about the safety of Rentosertib (INS018_055).

In this study, Rentosertib (INS018_055) will be compared to a placebo (a look-alike substance that contains no drug) to investigate if Rentosertib (INS018_055) works to treat Idiopathic Pulmonary Fibrosis.

연구 개요

연구 유형

중재적

등록 (추정된)

320

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Anhui
      • Hefei, Anhui, 중국
        • 아직 모집하지 않음
        • Anhui Provincial Hospital
      • Hefei, Anhui, 중국
        • 아직 모집하지 않음
        • Anhui Chest Hospital
    • Beijing Municipality
      • Beijing, Beijing Municipality, 중국
        • 모병
        • Peking Union Medical College Hospital
      • Beijing, Beijing Municipality, 중국
        • 모병
        • Beijing Friendship hospital, Capital Medical University
      • Beijing, Beijing Municipality, 중국
        • 아직 모집하지 않음
        • Beijing Chaoyang Hospital, Capital Medical University
    • Fujian
      • Fuzhou, Fujian, 중국
        • 아직 모집하지 않음
        • Fuzhou University Affiliated Provincial Hospital
      • Xiamen, Fujian, 중국
        • 모병
        • The Second Affiliated Hospital of Xiamen Medical College
    • Guangdong
      • Guangzhou, Guangdong, 중국
        • 모병
        • The First Affiliated Hospital of Guangzhou Medical University
      • Guangzhou, Guangdong, 중국
        • 아직 모집하지 않음
        • Nanfang Hospital, Southern Medical University
    • Guangxi
      • Nanning, Guangxi, 중국
        • 아직 모집하지 않음
        • The First Affiliated Hospital of Guangxi Medical University
    • Hainan
      • Haikou, Hainan, 중국
        • 모병
        • Hainan General Hospital
    • Hebei
      • Shijiazhuang, Hebei, 중국
        • 아직 모집하지 않음
        • The Second Hospital of Hebei Medical University
      • Shijiazhuang, Hebei, 중국
        • 아직 모집하지 않음
        • Hebei Medical University Third Hospital
    • Henan
      • Anyang, Henan, 중국
        • 모병
        • The People's Hospital of Anyang City
      • Nanyang, Henan, 중국
        • 모병
        • Nanyang First People's Hospital
      • Zhengzhou, Henan, 중국
        • 아직 모집하지 않음
        • Henan Provincial People's Hospital
      • Zhengzhou, Henan, 중국
        • 아직 모집하지 않음
        • The First Affiliated Hospital of Zhengzhou University
    • Hubei
      • Wuhan, Hubei, 중국
        • 아직 모집하지 않음
        • Renmin Hospital of Wuhan University
      • Wuhan, Hubei, 중국
        • 아직 모집하지 않음
        • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
      • Yichang, Hubei, 중국
        • 아직 모집하지 않음
        • Yichang Central People's Hospital
    • Hunan
      • Changsha, Hunan, 중국
        • 아직 모집하지 않음
        • The Second Xiangya Hospital of Central South University
      • Changsha, Hunan, 중국
        • 아직 모집하지 않음
        • The Xiangya Hospital of Central South University
    • Inner Mongolia
      • Hohhot, Inner Mongolia, 중국
        • 아직 모집하지 않음
        • The Affiliated Hospital of Inner Mongolia Medical University
    • Jiangsu
      • Nanjing, Jiangsu, 중국
        • 모병
        • Nanjing Drum Tower Hospital
      • Xuzhou, Jiangsu, 중국
        • 아직 모집하지 않음
        • The Affiliated Hospital of Xuzhou Medical University
    • Jiangxi
      • Nanchang, Jiangxi, 중국
        • 아직 모집하지 않음
        • Jiangxi Provincial People' Hospital
    • Jilin
      • Changchun, Jilin, 중국
        • 아직 모집하지 않음
        • The Second Hospital of Jilin University
    • Liaoning
      • Shenyang, Liaoning, 중국
        • 아직 모집하지 않음
        • Shengjing Hospital of China Medical University
    • Shaanxi
      • Xi'an, Shaanxi, 중국
        • 모병
        • The Second Affiliated Hospital of Xi'an Jiaotong University
      • Xi'an, Shaanxi, 중국
        • 모병
        • The First Affiliated Hospital of Xi'an Medical College
    • Shandong
      • Jinan, Shandong, 중국
        • 아직 모집하지 않음
        • Qilu Hospital of Shandong University
      • Jinan, Shandong, 중국
        • 아직 모집하지 않음
        • Introduction of the First Affiliated Hospital of Shandong First Medical University
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, 중국
        • 모병
        • Shanghai Pulmonary Hospital Affiliated to Tongji University
    • Shanxi
      • Taiyuan, Shanxi, 중국
        • 아직 모집하지 않음
        • Shanxi Bethune Hospital
      • Yuncheng, Shanxi, 중국
        • 아직 모집하지 않음
        • Yuncheng Central Hospital
    • Sichuan
      • Chengdu, Sichuan, 중국
        • 아직 모집하지 않음
        • West China Hospital, Sichuan University
      • Chengdu, Sichuan, 중국
        • 아직 모집하지 않음
        • Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, 중국
        • 아직 모집하지 않음
        • Tianjin Medical University General Hospital
      • Tianjin, Tianjin Municipality, 중국
        • 아직 모집하지 않음
        • Tianjin Chest Hospital
    • Xinjiang
      • Ürümqi, Xinjiang, 중국
        • 아직 모집하지 않음
        • The First Affiliated Hospital of Xinjiang Medical University
    • Yunnan
      • Kunming, Yunnan, 중국
        • 아직 모집하지 않음
        • The First People Hospital of Yunnan Province
    • Zhejiang
      • Hangzhou, Zhejiang, 중국
        • 아직 모집하지 않음
        • Sir Run Run Shaw Hospital Zhejiang University School of Medicine
      • Hangzhou, Zhejiang, 중국
        • 모병
        • Affiliated Hangzhou First People's Hospital,School of Medicine, Westlake University
      • Jiaxing, Zhejiang, 중국
        • 아직 모집하지 않음
        • The First Hospital of Jiaxing
      • Ningbo, Zhejiang, 중국
        • 아직 모집하지 않음
        • Ningbo Medical Center Lihuili Hospital
      • Ningbo, Zhejiang, 중국
        • 아직 모집하지 않음
        • The First Affiliated Hospital of Ningbo University
      • Wenzhou, Zhejiang, 중국
        • 아직 모집하지 않음
        • The First Affiliated Hospital of Wenzhou Medical University

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

설명

Inclusion Criteria:

  1. An informed consent form (ICF) signed and dated at screening (Visit 1), prior to initiation of any study related procedures, and in accordance with ICH-GCP and local legislation.
  2. Patients aged ≥40 years at time of signing the ICF.
  3. Diagnosis of IPF based on the 2022 ATS/ERS/JRS/ALAT Clinical Practice Guideline, confirmed by an HRCT chest scan within 3 months prior to screening visit.
  4. UIP or probable UIP with fibrosis extent >10% at HRCT.
  5. Meet all the following criteria during the screening period:

    1. FVC ≥45% predicted of normal
    2. FEV1/FVC ≥0.7
    3. DLCO (corrected for hemoglobin) ≥25% and <80% predicted of normal.
  6. Background antifibrotic therapies are allowed, patients may be either:

    1. on a stable therapy with nintedanib or pirfenidone as monotherapy for at least 12 weeks prior to screening visit and during the screening period and are planning to stay on this background treatment after randomization.
    2. not on a treatment with nintedanib or pirfenidone for at least 8 weeks prior to screening visit and during the screening period and do not plan to start or restart antifibrotic therapy.
  7. Estimated minimum life expectancy of at least 30 months for non-IPF related disease in the opinion of the investigator.
  8. Male patients and female patients of childbearing potential agree to use highly effective contraception/preventive exposure measures from the time of the first dose of the study drug (for the male patient) or the signing of the ICF (for the female patient) until 90 days after the last dose of the study drug.

Exclusion criteria:

  1. Interstitial lung disease associated with known primary diseases (eg, autoimmune disease-related interstitial lung diseases, sarcoidosis and amyloidosis), exposures (eg, radiation, silica, asbestos, and coal dust), or drugs (eg, amiodarone).
  2. Previous participation in a clinical study with rentosertib (active or placebo).
  3. Concurrent participation in another interventional drug, device, or biological investigational research study, or use of an investigational agent within 5 half-lives of the agent (or within 8 weeks when half-life is unknown) prior to screening is not allowed.
  4. Pulmonary hypertension that is clinically relevant or severe as deemed by the investigator, or other clinically significant pulmonary abnormalities.
  5. Unstable cardiovascular or other disease within 6 months prior to the screening visit or during the screening period.
  6. Presence of other clinically significant airway disease that may, in the opinion of the investigator, impact the study safety or efficacy objectives, such as asthma, bronchiectasis, cystic fibrosis, active aspergillosis, active tuberculosis, or other serious concomitant respiratory disorder other than pulmonary fibrosis.
  7. Acute exacerbation of IPF within 6 months prior to screening visit and/or during the screening period.
  8. Patients with underlying chronic liver disease (Child Pugh A, B, or C hepatic impairment), hepatic steatosis (including non-alcoholic steatohepatitis and/or other types of fatty liver diseases).
  9. Patients with Gilbert's disease
  10. Relevant chronic or acute infections including human immunodeficiency virus (HIV) and clinically significant viral hepatitis.
  11. Aspartate aminotransferase or alanine aminotransferase ≥1.5 × upper limit of normal (ULN), and/or total bilirubin ≥1.5 × ULN, and/or gamma glutamyl transferase ≥3 × ULN, and/or alkaline phosphatase ≥1.5 × ULN at screening.
  12. Estimated glomerular filtration rate <60 mL/min/1.73m2 at screening.
  13. Patient with 12-lead ECG demonstrating corrected QT interval by Fridericia (QTcF) >450 ms for males and >470 ms for females at screening (Visit 1).
  14. Patient with a history of lung volume reduction surgery or lung transplant.
  15. Current smoker and/or cotinine (smoking) test positive.
  16. History of drug abuse, drug use, or alcohol abuse within the past 3 months.
  17. Major surgery performed within 3 months prior to screening visit, during the screening period, or have major surgery planned during the study period.
  18. Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening visit.
  19. Use of any of the following therapies within 4 weeks prior to screening visit and during the screening period or planned during the study: warfarin and immunosuppressive medications.
  20. Patients currently taking endothelin receptor antagonists,phosphodiesterase type 5 inhibitors, soluble guanylate cyclase modulators, prostacyclin analogues and prostanoids, or activin signaling inhibitor.
  21. Patients currently on a treatment with nerandomilast within 8 weeks prior to screening visit and during the screening period.
  22. Use of any of the following drugs within 2 weeks prior to Visit 1/screening or planned during the duration of the study

    1. Strong and moderate cytochrome P450 3A4 or 1A2 inhibitors/inducers
    2. Medications associated with substantial risk for prolongation of corrected QT interval.
  23. Patients who have consumed grapefruit or grapefruit juice, pomelo, Seville orange or Seville orange-containing products within 48 hours before Day 1.
  24. Patients who used hormone replacement therapy in the 4 weeks prior to randomization. No hormone replacement therapy use is allowed during the study.
  25. Patients with known hypersensitivity or contraindications to serine/threonine kinase inhibitors.
  26. Any condition that would interfere with the interpretation of study assessments or impair study participation.
  27. Any physical or psychological conditions or circumstance that, in the opinion of the investigator, may make a patient unsuitable for inclusion or unlikely or unable to complete the study or comply with study procedures and requirements.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Active
Patients assigned will receive ISN018_055 tablets orally QD for 52 weeks
Dosage form: Tablets; Frequency of administration: Orally QD. Other Names: Rentosertib
위약 비교기: Placebo
Patients assigned will receive matching placebo orally QD for 52 weeks
제형: 정제; 투여 빈도: 경구 1일 1회.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
기간
the annual rate of forced vital capacity (FVC; mL) decline over 52 weeks.
기간: Weeks 0,4,12,26,39,52
Weeks 0,4,12,26,39,52

2차 결과 측정

결과 측정
측정값 설명
기간
time to first occurrence of any disease progression
기간: up to 52 weeks
including 1) percent predicted forced vital capacity decrease relative to baseline greater than 10%, 2) acute exacerbation of IPF, 3) respiratory-related hospitalization, or 4) death due to respiratory
up to 52 weeks
change from baseline to Week 52 in quantitative computed tomography-derived lung fibrosis burden on high-resolution computed tomography(HRCT)
기간: week 52
week 52
change from baseline in quality of life (QoL) as measured by the patient-reported outcomes questionnaires using King's Brief Interstitial Lung Disease questionnaire (K BILD)
기간: Weeks 0,4,12,26,39,52
Weeks 0,4,12,26,39,52
change from baseline in QoL as measured by the patient-reported outcomes questionnaires using Living with Pulmonary Fibrosis(L-PF)
기간: Weeks 0,4,12,26,39,52
Weeks 0,4,12,26,39,52
change from baseline in hemoglobin-corrected diffusing capacity of the lung for carbon monoxide (DLCO) over 52 weeks
기간: Weeks 0, 52
Weeks 0, 52

기타 결과 측정

결과 측정
기간
Incidence of treatment-emergent adverse events(Safety and Tolerability), and clinically significant changes in physical examination,vital signs,safety laboratory test
기간: up to 56 weeks
up to 56 weeks
Clinically significant changes in the 12-lead electrocardiogram(ECG) of ECG QTcF Interval
기간: Weeks 0,2,4,8,12,26,39,52
Weeks 0,2,4,8,12,26,39,52
Clinically significant changes in the 12-lead electrocardiogram(ECG) of ECG Heart Rate
기간: Weeks 0,2,4,8,12,26,39,52
Weeks 0,2,4,8,12,26,39,52
changes from baseline in serum proteome by high throughput proteomic analysis at Weeks 12, 26, and 52
기간: weeks 0, 12 ,26, and 52
weeks 0, 12 ,26, and 52
changes from baseline in serum bone biomarker of procollagen 1 intact N-terminal propeptide [P1NP]
기간: weeks 0, 52
weeks 0, 52
changes from baseline in serum bone biomarker of C-terminal telopeptide [CTX]
기간: weeks 0, 52
weeks 0, 52

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 9월 9일

기본 완료 (추정된)

2029년 10월 30일

연구 완료 (추정된)

2029년 10월 30일

연구 등록 날짜

최초 제출

2026년 6월 22일

QC 기준을 충족하는 최초 제출

2026년 7월 1일

처음 게시됨 (실제)

2026년 7월 7일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 17일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 14일

마지막으로 확인됨

2026년 6월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다